Adjuvants: Making Vaccines Immunogenic

Gregg N. Milligan

doi:10.1002/9781118638033.ch6

Adjuvants: Making Vaccines Immunogenic

Gregg N. Milligan

Pediatrics

Research output: Chapter in Book/Report/Conference proceeding › Chapter

2 Scopus citations

Abstract

The utilization of recombinant proteins in vaccines is advantageous from a safety perspective, but these proteins often are very poor at inducing an immune response. In this circumstance, the vaccine antigen can be delivered with substances known as adjuvants to increase the magnitude or duration of the immune response. This chapter examines the characteristics of a good adjuvant, the different types of adjuvants currently licensed or under development in the United States and European Union, and what is known about their mechanism of action. Future trends in adjuvant-driven development of specific types of immune responses and development of novel adjuvants for antigen delivery to specific tissues are also discussed.

Original language	English (US)
Title of host publication	Vaccinology
Subtitle of host publication	An Essential Guide
Publisher	Wiley-Blackwell
Pages	93-108
Number of pages	16
ISBN (Electronic)	9781118638033
ISBN (Print)	9780470656167
DOIs	https://doi.org/10.1002/9781118638033.ch6
State	Published - Dec 9 2014

Keywords

Adjuvants
Alum
Antigens
Emulsion
Human vaccines
Pathogen recognition receptors
Pathogen-associated molecular patterns
Reactogenicity
Veterinary vaccines

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/9781118638033.ch6

Cite this

@inbook{596d1a2839e54eecb610dd9addd52297,

title = "Adjuvants: Making Vaccines Immunogenic",

abstract = "The utilization of recombinant proteins in vaccines is advantageous from a safety perspective, but these proteins often are very poor at inducing an immune response. In this circumstance, the vaccine antigen can be delivered with substances known as adjuvants to increase the magnitude or duration of the immune response. This chapter examines the characteristics of a good adjuvant, the different types of adjuvants currently licensed or under development in the United States and European Union, and what is known about their mechanism of action. Future trends in adjuvant-driven development of specific types of immune responses and development of novel adjuvants for antigen delivery to specific tissues are also discussed.",

keywords = "Adjuvants, Alum, Antigens, Emulsion, Human vaccines, Pathogen recognition receptors, Pathogen-associated molecular patterns, Reactogenicity, Veterinary vaccines",

author = "Milligan, {Gregg N.}",

note = "Publisher Copyright: {\textcopyright} 2015 John Wiley & Sons, Ltd.",

year = "2014",

month = dec,

day = "9",

doi = "10.1002/9781118638033.ch6",

language = "English (US)",

isbn = "9780470656167",

pages = "93--108",

booktitle = "Vaccinology",

publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Adjuvants

T2 - Making Vaccines Immunogenic

AU - Milligan, Gregg N.

PY - 2014/12/9

Y1 - 2014/12/9

N2 - The utilization of recombinant proteins in vaccines is advantageous from a safety perspective, but these proteins often are very poor at inducing an immune response. In this circumstance, the vaccine antigen can be delivered with substances known as adjuvants to increase the magnitude or duration of the immune response. This chapter examines the characteristics of a good adjuvant, the different types of adjuvants currently licensed or under development in the United States and European Union, and what is known about their mechanism of action. Future trends in adjuvant-driven development of specific types of immune responses and development of novel adjuvants for antigen delivery to specific tissues are also discussed.

AB - The utilization of recombinant proteins in vaccines is advantageous from a safety perspective, but these proteins often are very poor at inducing an immune response. In this circumstance, the vaccine antigen can be delivered with substances known as adjuvants to increase the magnitude or duration of the immune response. This chapter examines the characteristics of a good adjuvant, the different types of adjuvants currently licensed or under development in the United States and European Union, and what is known about their mechanism of action. Future trends in adjuvant-driven development of specific types of immune responses and development of novel adjuvants for antigen delivery to specific tissues are also discussed.

KW - Adjuvants

KW - Alum

KW - Antigens

KW - Emulsion

KW - Human vaccines

KW - Pathogen recognition receptors

KW - Pathogen-associated molecular patterns

KW - Reactogenicity

KW - Veterinary vaccines

UR - http://www.scopus.com/inward/record.url?scp=84976417314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976417314&partnerID=8YFLogxK

U2 - 10.1002/9781118638033.ch6

DO - 10.1002/9781118638033.ch6

M3 - Chapter

AN - SCOPUS:84976417314

SN - 9780470656167

SP - 93

EP - 108

BT - Vaccinology

PB - Wiley-Blackwell

ER -

Adjuvants: Making Vaccines Immunogenic

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this